ReviewOncogene2010
Molecular pathogenesis of peripheral neuroblastic tumors.
Review in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 96 citations in OpenAlex.
- Identification of Prognostic Biomarkers in Gene Expression Profile of Neuroblastoma Via Machine Learning.Pediatric discovery · 2025Article
- 15 Years Old ALK Gene from Birth to Adolescence; Where to in NBL.Current oncology reports · 2025Review
- [Peripheral neuroblastic tumors in childhood].Pathologie (Heidelberg, Germany) · 2023Review
- Soluble NKG2D ligands impair CD8Oncology letters · 2023Article
- NONO enhances mRNA processing of super-enhancer-associated GATA2 and HAND2 genes in neuroblastoma.EMBO reports · 2023Article
- Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT).Cancers · 2021Review
- The Dramatic Consequences of an Accidental Ligation of the Celiac Trunk during Surgery Performed on a Child with Neuroblastoma.International journal of environmental research and public health · 2021Article
- A Novel Germline Compound Heterozygous Mutation ofFrontiers in genetics · 2021Article
- Monomerization of ALK Fusion Proteins as a Therapeutic Strategy inFrontiers in oncology · 2020Article
- Neuroblastoma of the Urinary Bladder in an Infant.European journal of pediatric surgery reports · 2019Article
- Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.BMC cancer · 2016Article
- HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.Oncotarget · 2016Article
- The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.Forum on immunopathological diseases and therapeutics · 2016Article
- The zebrafish as a model for studying neuroblastoma.Cancer cell international · 2016Review
- Detection of tumor ALK status in neuroblastoma patients using peripheral blood.Cancer medicine · 2015Article
- Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts.PLoS computational biology · 2015Article
- Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.British journal of cancer · 2015Article
- Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.Oncotarget · 2014Article
- Article
- ALK-driven tumors and targeted therapy: focus on crizotinib.Pharmacogenomics and personalized medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma (NB) is an embryonal cancer of the sympathetic nervous system observed in early childhood, characterized by a broad spectrum of clinical behaviors, ranging from spontaneous regression to fatal outcome despite aggressive therapies. NB accounts for 8-10% of pediatric cancers and 15% of the deaths attributable to malignant conditions in children. Interestingly, NB may occur in various contexts, being mostly sporadic but also familial or syndromic. This review focuses on recent advances in the identification of the genes and mechanisms implicated in NB pathogenesis. Although the extensive characterization of the genomic aberrations recurrently observed in sporadic NBs provides important insights into the understanding of the clinical heterogeneity of this neoplasm, analysis of familial and syndromic cases also unravels essential clues on the genetic bases of NB. Recently, the ALK gene emerged as an important NB gene, being implicated both in sporadic and familial cases. The identification of gene expression signatures associated with patient's outcome points out the potential of using gene expression profiling to improve clinical management of patients suffering from NB. Finally, based on recent observations integrating genomic analyses, biological data and clinical information, we discuss possible evolution/progression schemes in NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.